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Abstract
This study evaluated the effects of bone marrow-derived mesenchymal stem cells (BMSCs) or their conditioned medium
(CM) on the repair and prevention of Acute Kidney Injury (AKI) induced by gentamicin (G). Animals received daily injections
of G up to 20 days. On the 10th day, injections of BMSCs, CM, CM+trypsin, CM+RNase or exosome-like microvesicles
extracted from the CM were administered. In the prevention groups, the animals received the BMSCs 24 h before or on the
5th day of G treatment. Creatinine (Cr), urea (U), FENa and cytokines were quantified. The kidneys were evaluated using
hematoxylin/eosin staining and immunohystochemistry. The levels of Cr, U and FENa increased during all the periods of G
treatment. The BMSC transplantation, its CM or exosome injections inhibited the increase in Cr, U, FENa, necrosis, apoptosis
and also increased cell proliferation. The pro-inflammatory cytokines decreased while the anti-inflammatory cytokines
increased compared to G. When the CM or its exosomes were incubated with RNase (but not trypsin), these effects were
blunted. The Y chromosome was not observed in the 24-h prevention group, but it persisted in the kidney for all of the
periods analyzed, suggesting that the injury is necessary for the docking and maintenance of BMSCs in the kidney. In
conclusion, the BMSCs and CM minimized the G-induced renal damage through paracrine effects, most likely through the
RNA carried by the exosome-like microvesicles. The use of the CM from BMSCs can be a potential therapeutic tool for this
type of nephrotoxicity, allowing for the avoidance of cell transplantations.
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Introduction
Acute kidney injury (AKI) is a syndrome of rapidly declining
renal function induced by a number of different insults [1].
The mortality rate of hospital acquired AKI currently ranges
from 30 to 80%, and recent dialysis techniques, such as continuous
renal replacement therapy and others, have had no significant
impact on overall mortality. Furthermore, the efforts to develop
new pharmacological therapies have been largely unsuccessful [2].
Gentamicin (G) is an aminoglycoside antibiotic widely used for
the treatment of gram-negative infections [1], and it is a well-
known cause of renal toxicity mainly characterized by proximal
tubular necrosis, alterations in glomerular hemodynamics, and a
decrease in both the glomerular plasma flow and in the
ultrafiltration coefficient [3–6]. The use of toxic antibiotics is
increasing due to antimicrobial resistance, especially in intensive
care units; therefore, new strategies are necessary to treat or
prevent G-induced nephrotoxicity.
BMSCs, also known as marrow stromal cells [7] or mesenchy-
mal progenitor cells [8], are defined as self-renewable, multipotent
progenitor cells with the capacity to differentiate into several
distinct mesenchymal lineages [9–14]. Several studies have
suggested that stem cells may protect AKI experimental models
from cisplatin, glycerol and ischemia-reperfusion injury [10–12],
but the mechanism by which BMSCs functionally contribute to
renal tubule regeneration in AKI is a matter of debate. These
experimental models are characterized by extensive necrosis of the
proximal and distal tubules that may favor BMSCs migration into
these areas. However, the therapeutic potential of exogenously
administered BMSCs in a model of G-induced AKI has not been
evaluated.
The mechanism for the effects of BMSCs remains controversial
because some studies have reported that the injected BMSCs
infiltrate the kidney and directly populate the injured renal tubule
[12]. Other studies have found only transient evidence of injected
BMSCs in the renal vasculature and no evidence for direct
BMSCs incorporation into the tubules during the repair processes
[13], suggesting paracrine effects.
This study was undertaken to evaluate if BMSCs were capable
of minimizing or preventing the AKI induced by G. In our
experiments, the cells were localized in the injured kidney,
reducing the nephrotoxic effects of G. Interesting, the BMSC
conditioned medium (CM) also minimized the G effects,
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supporting the hypothesis that BMSCs may exert a paracrine
effect on the filtration function and in the damaged tissue. Because
the protective effect of the CM was blunted by RNase during a
long period of incubation, these paracrine effects may be mediated
mainly by the RNA-like factors released by BMSCs into the
medium. Therefore, in future clinical applications, it may be
possible to treat this nephrotoxicity using CM alone, thus avoiding
cell transplantations.
Results
First, we characterized the BMSCs by flow cytometry and the
analysis of the cell differentiation. Figure 1A and B show the flow
cytometry of the BMSCs cultured on the 4th passage. There was a
positive staining in BMSCs for STRO1 (88.163.8%), CD73
(68.5617.7%), CD17 (88.664.1%), CD90 (9563.6%), CD29
(98.861.0%), CD44 (9061.7%) and CD105 (78613.0%) when
compared to the negative control. There was no positive staining
for CD11b (4.460.5%), CD45 (1.560.4%) and CD34
(1.860.8%), and all of them were used as negative controls for
BMSCs. Figure 1C also shows the differentiation of BMSCs into
adipocytes and osteocytes.
To analyze the hypothesis that BMSCs could treat the AKI
induced by G, the cells were transplanted into the AKI rats.
Table 1 presents the serum creatinine (Cr), urea and FENa levels
in the Wistar rats treated with a vehicle (CTL) or G for 10, 11, 12,
15 or 20 days and the corresponding G groups treated with
BMSCs (Figure 2A and C).
Serum Cr, U concentrations and FENa after 10, 11, 12, 15 and
20 days of G treatment increased in comparison to the CTL group
(p,0.05) (Table 1). When the animals were transplanted with a
single injection of BMSCs on the 10th day, there was a significant
decrease in the serum Cr, U and FENa in comparison to the G
only group at all days of the treatment with the antibiotic (Table 1).
This result suggests that one single injection of BMSCs could
inhibit the AKI induced by up to 20 days of G administration.
Because it was observed that BMSC transplantation could
inhibit the AKI induced by G, we determined whether these cells
could prevent this injury when transplanted before the G
treatment or before significant alteration in the functional
parameters of Cr, U and FENa.
Table 2 shows the biochemical parameters in the prevention
groups, where the animals were transplanted with BMSC on the
1st day before the beginning of the G treatment or at the 5th day of
the treatment with G; no significant differences were observed in
the functional parameters (Figure 2A and B). It was observed that
there were no differences in Cr, U and FENa between the G group
and the G group transplanted with BMSCs one day before the
treatment with this antibiotic. Additionally, the BMSC transplan-
tation after 5 days of treatment with G did not inhibit the increase
in functional parameters induced by the antibiotic after 10 days of
treatment (Table 2).
It is reasonable to suggest that the protective effect of the
BMSCs was not observed because there was no homing of the
BMSCs in the prevention group. Therefore, we analyzed the
presence of the Y chromosome of BMSCs from male rats in the
kidney of the female animals treated with G (Figure 3). All of the
groups treated with G were analyzed, but in the next sections, we
show the results from the prevention groups and from the animals
treated with G for 15 days that received BMSC on the 10th day
because the injury was more severe in this group. Additional
information can be found in Figure S1.
The Y chromosome was detected in the interstitial and
peritubular area of the kidney in male rats (used as the positive
control) and in female rats treated with G for 15 days that received
BMSCs after 10 days of treatment (G15+BMSC10). Nevertheless,
we did not localize the Y chromosome in the kidney of the rats
treated with G for 10 days when the cells were transplanted 24 h
before the beginning of the antibiotic administration (P-24+G10).
This result corroborates the hypothesis that the injury stimulus is
necessary for the homing of the cells. Interestingly, we detected the
Y chromosome in the kidney of the animals treated with G for 10
days that received the BMSC at the 5th day (Figure 3).
It has been shown that the main mechanism of action of BMSCs
is paracrine [31]. To further study this mechanism, we analyzed
the hypothesis that the conditioned medium (CM) of BMSCs
could also inhibit the G-induced AKI. Table 3 shows the effects of
a single injection of the CM of BMSCs on the G-induced AKI.
The Cr, U and FENa levels decreased in the G group treated with
CM on the 10th day of the antibiotic treatment in comparison to
the group treated with G alone for 15 days (p,0.05).
Additionally, several studies have suggested that the paracrine
effect of BMSCs is mediated by protein or RNA (microRNA or
mRNA carried by microvesicles) [21]. To address this question, we
treated the conditioned medium with RNase A and trypsin for
12 h prior to injecting it into the rats. The protective effect of CM
was blunted after it was treated with RNase for 12 h (Table 3).
Figure 4A shows the 18S housekeeping gene expression in the
conditioned medium. The treatment with RNase (40 mg/ml)
significantly degraded the RNA in conditioned medium samples.
When the CM of BMSC was incubated with trypsin and was
administered to the rats during G treatment, the protective effect
of CM was not completely blunted, suggesting that the soluble
proteins in the CM are not entirely responsible for the protective
effect; another protective mechanism may contribute to this effect
(Table 3).
It is possible that the treatment of BMSCs with RNase A or
trypsin could damage the cells; to address this question, we
analyzed the viability of BMSCs either untreated or treated with
trypsin or RNase for 12 hours. However, there was no significant
difference in cell viability between BMSCs that were untreated or
treated (Figure 4B).
To evaluate the impact of the transplantation of BMSCs or its
CM on the severity of the tissue damage induced by G in the
kidney, a histological scoring was performed based on the number
of proximal tubules with damage (Figure 4C).
There was a significant increase in the histological scoring in the
G15 (51.662.3 injuries/100 mm
2) treated group compared with
the CTL group (260.06 injuries/100 mm2) (p,0.05). The BMSCs
transplanted or the CM injected on the 10th day significantly
protected the kidney from G administration over 15 days, as
observed in groups G15+BMSC10 (35.864.9 injuries/100 mm2)
and G15+CM10 (3161.9 injuries/100 mm2) (p,0.05). However,
when the animals were treated with the CM exposed to RNase
(G15+CM10+RNAse10), the lesions were maintained (43.663.4
injuries/100 mm2). It is interesting that in the prevention groups,
the effects of G were minimized when the BMSCs were given on
the 5th day of the treatment, but this result was not corroborated
by the functional parameters. The results for the other G-treated
groups can be found in Figure S2.
Figure 4C shows the immunohistochemistry for apoptotic cell
death and proliferation, as shown by its regulatory protein caspase
3 and the nuclear protein KI67. There was an increase in caspase
3 staining in the G15 (58.262.8%) group versus the G15+BMSC10
(24.464.2%) or G15+CM10 (25.560.5%) groups (p,0.05). The
protective effect of the CM was blunted when it was incubated
with RNase.
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For the proliferation of the cells, the G15+BMSC10 (55.560.5
nuclei/100 mm2) and G15+CM10 (58.262.8 nuclei/100 mm2)
animals showed an increase in the nuclear expression of KI67 in
comparison to the G15 (5.260.4 nuclei/100 mm
2; p,0.05) and
CTL15 (3.260.4 nuclei/100 mm
2) (p,0.05) animals. The prolif-
eration induced by the CM was inhibited when the CM was
treated with RNase (39.361.1 nuclei/100 mm2) (p,0.05). The
animals treated with only BMSC or CM showed no increase in
KI67 (Figure 4D).
To further investigate the mechanism of protection in the CM,
we extracted exosome-like microvesicles from CM treated or not
with RNase.
Figure 5A shows the transmission electron microscopy (TEM) of
exosome-like microvesicles extracted from the conditioned medi-
um. Figure 5B shows that the RNAse treatment significantly
degraded the RNA carried by the exossome as shown by the
housekeeping gene 18S expression. The treatment of the animals
with these exosomes (100 mg/ml of protein) significantly induced
cellular proliferation, as shown by Figure 5C and inhibited the
tubular necrosis induced by G in these animals (Figure 5C and D).
This effect was inhibited when the CM was treated with RNase
and the exosomes were extracted (Figure 5C and D). This result
suggests that the protective paracrine effect of the CM is mediated,
at least in part, by exosome-like microvesicles released by the
BMSC.
Several mechanisms have been proposed to explain the
protective effect of BMSCs. There is evidence for both pro- and
anti-inflammatory actions of BMSCs. To further address these
mechanisms, we analyzed several pro- and anti-inflammatory
cytokines in the serum of Wistar rats in the CTL, G, G+BMSC
Figure 1. (A) FACS analysis and (B) quantification showing the monoclonal antibody expression [%] of BMSCs. Data are expressed as the mean 6
S.E.M. (* p,0.05) vs. CD45, CD34 and CD11b. (C) The differentiation of BMSCs into adipocytes and osteocytes. Undifferentiated (non-induced) BMSCs
were maintained in the control medium as a negative control.
doi:10.1371/journal.pone.0044092.g001
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and G+CM groups after 15 and 20 days of treatment with the
antibiotic to prove a sustained protective effect of the CM or the
cells (Figure 6). There were significant increases in the pro-
inflammatory cytokines IL6, INF-c and TNF-a and a decrease in
the anti-inflammatory cytokine IL10 in the G-treated groups,
indicating the inflammatory effects of G. When the rats received
BMSCs, the proinflammatory cytokines IL6, INF-c and TNF-a
decreased, while the anti-inflammatory cytokine increased com-
pared to the G groups.
The same pattern was observed when the animals were treated
with the CM. There was a decrease in IL6, INF-c and TNF-a and
an increase in IL10.
There were no significant differences in cytokine concentrations
between the BMSC transplanted and CM-treated animals,
suggesting that in our experimental model, the main effects of
BMSCs are paracrine (Figure 6).
Discussion
In clinical practice, an aminoglycoside injury is the most
common cause for a nephrotoxic complication, and no signifi-
cantly effective new therapy in humans has been introduced in
decades [6].
In the current study, the animals were treated with G injections
for up to 20 days to establish the time point of the G treatment that
best reproduces what is observed in clinical practice. The
treatment with G for 10 days was able to induce AKI [6] with
an increase in serum creatinine, urea, FENa and apoptosis and a
decrease in cell proliferation. Additionally, there was an increase in
the pro-inflammatory and a decrease in the anti-inflammatory
plasmatic cytokines that reflect the inflammatory process induced
by G in the kidney. These results are in agreement with the
findings of other studies [14–16].
To study the role of BMSCs on the treatment of G, BMSCs
were administered on the 10th day of treatment, and the rats
continued receiving G for up to 20 days. During these periods, the
cells were able to minimize the deleterious effects caused by G,
thereby decreasing serum creatinine, urea, FENa and pro-
inflammatory cytokines while increasing an anti-inflammatory
cytokine. Additionally, there were decreases in the tubular lesions,
as shown by the caspase 3 marker, along with increases in cell
proliferation. Similar effects were also demonstrated by others,
where the BMSCs were able to minimize renal damage in several
models of AKI, such as the cisplatin, adriamycin and ischemia/
reperfusion experimental models [17–19]. These authors reported
that the BMSCs accelerate the structural recovery of the kidney
Figure 2. The schematic of the experiment protocol. In the control group (CTL), the rats were treated with daily i.p. injections of a vehicle
(water), while the G groups received gentamicin (40 mg/Kg BW) continuously for 10, 11, 12, 15 or 20 days. For the prevention groups, the rats
received BMSC 16106 i.v. injections 24 hours before (G10+BMSC21) or in the 5th day (G10d+BMSC5) of a 10-day treatment with G. For the treated
groups, the rats received BMSC 16106 i.v. injections on the 10th day of G treatment and continued receiving G for an additional 1 (G11+BMSC10), 2
(G12+BMSC10), 5 (G15+BMSC10) or 10 (G20+BMSC10) days. For the conditioned media protocol, the rats received G (40 mg/Kg/BW, i.p., daily) or water
(CTL) for 15 or 20 days, and on the 10th day of the G treatment, the animals received 500 ml of a single dose of CM. In some experiments, the BMSCs
were cultured for 12 h with trypsin and a concentration of 100 ug/ml (CM+TPS, 100 mg/ml) or RNase A at a concentration of 40 ug/ml, 280 Units
(CM+RNAse) in DMEM without FBS.
doi:10.1371/journal.pone.0044092.g002
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after AKI, and, more importantly, that they confer therapeutic
benefits.
We also evaluated whether BMSCs could prevent the AKI
caused by G. It was observed that when BMSCs were
administrated prior to treatment with G on the 5th day of
treatment, the full impact of G on the kidney was not blunted.
Previous studies have shown that on the 5th day of treatment with
G, renal injury is already present [4], and BMSCs may be
recruited to the injury site but not at a level sufficient to confer a
protective effect.
The functional protection by BMSCs can be the consequence of
the capacity of these cells to engraft the damaged kidney. We
evaluated the presence of BMSCs in renal tissue by using the
chromosome Y localization strategy. It was detected in all of the
groups analyzed, indicating that BMSCs migrate to the local site of
the injury and stay during the continuous injury period. However,
the chromosome Y was not detected in the prevention group
24 hours before the insult with G, suggesting that the BMSCs were
rapidly removed because no lesions were present in renal tissue to
allow for the docking of stem cells. To our knowledge, this is the
first report demonstrating that BMSCs are not able to prevent the
injury induced by G prior to its use but that it is possible to reduce
tissue injury if BMSC transplantation is performed during the
early stages of AKI. However, because no improvement in the
functional parameters was observed, it is necessary to further
evaluate the impact of this effect on long-term nephrotoxicity. The
paracrine effect of the BMSCs was confirmed by the administra-
tion of the CM on the 10th day of G treatment, which resulted in
reduced damage caused by the antibiotic in both functional and
histopathological parameters. Strikingly, the CM was able to
reduce the creatinine, urea, FENa and pro-inflammatory cytokine
levels (e.g., IL6, IFT-c and TNF-a) and to increase the anti-
inflammatory cytokine IL10. These results suggest that BMSCs
might be able to protect the injured tissue potentially by releasing
factors with repair proprieties [20].
Other studies have demonstrated that micro- and mRNA and
other factors are present in the microvesicles released by BMSCs
and that these factors could mediate the paracrine effects [21]. In
the present study, the CM was treated with RNase or trypsin; it
was observed that the treatment of the CM with RNase, but not
trypsin, completely abolished the protective effect, indicating the
participation of RNA-like products in these processes as observed
previously [21,22]. Additionally, the same protective effect was
observed when the animals were treated with these microvesicles.
When exosome-like vesicles were extracted from the CM treated
with RNase, the RNA carried in these exosomes was also
degraded.
Conclusions
Our results demonstrate that the effects of the BMSCs or their
conditioned medium enhanced the recovery of renal function in
an aminoglycoside AKI model and that the protective effects were
mediated by RNA carried by the exosomes/microvesicles in the
CM. These results provide a rationale for a potential therapeutic
tool for nephrotoxic AKI treatment. Moreover, because the effect
of the administration of the conditioned medium from BMSCs
blunted the effects of G, it is possible to avoid cell transplantation
in the treatment of this nephrotoxicity.
Materials and Methods
Culture of BMSCs
The experimental protocol of the present work was approved by
the ethics committee of the Universidade Federal de Sa˜o Paulo
(20/2008). Bone marrow (BM) was obtained from 12-week-old
male Wistar rats. Briefly, rats were euthanized, and the femurs and
tibias were aseptically removed. The BM was flushed from the
bone with DMEM medium (Sigma, St. Louis MO, USA)
containing 5% FCS (Invitrogen, Paisley, Scotland) plus penicil-
lin/streptomycin (100 U/ml to 0.1 mg/ml; Invitrogen) and then
filtered through a 100-mm sterile filter (Falcon) to produce a single-
cell suspension. The BMSCs were obtained by their tendency to
adhere tightly to plastic culture dishes, as previously described
[23,24]. The BM cells were plated in culture dishes with DMEM
plus 20% FCS and penicillin-streptomycin (100 U/ml to 0.1 mg/
ml) and allowed to adhere for 24 h. Non-adherent cells were then
removed. The medium was changed regularly every 3 days. After
2 to 3 weeks, adherent cells were detached by trypsin-EDTA (0.5
to 0.2 g/L; Invitrogen) and used for the in vivo experiments. Cells
were utilized in the 4th passage for all experiments. For the
conditioned medium-treated groups, the BMSCs were cultured
with DMEM without SBF for 24 hours. After this period, the CM
was collected and administered (500 ml) into the caudal vein of the
animals.
Table 1. The biochemical results from the treatment groups
transplanted with BMSCs.
GROUPS sCr (mg/dl) sU (mg/dl) FENa (%)
CTL10d 0.560.02 2462.0 0.660.02
CTL11d 0.660.03 2663.0 0.760.02
CTL12d 0.760.02 3266.0 0.860.05
CTL15d 0.760.04 2964.0 0.860.05
CTL20d 0.560.03 3468.0 0.660.02
G10d 1.960.07* 9862.0* 1.560.04*
G11d 2.360.04* 10461.0* 1.760.03*
G12d 2.760.03* 11961.0* 1.760.01*
G15d 2.960.04* 12865.0* 2.160.04*
G20d 3.460.08* 10461.0* 1.560.04*
G11+BMSC10 1.060.04# 6462.0# 1.060.02#
G12+BMSC10 0.760.03# 5461.0# 0.760.01#
G15+BMSC10 0.660.01# 4161.0# 0.760.03#
G20+BMSC10 0.960.02# 6863.0# 1.060.01#
Data are expressed as the mean 6 S.E.M. One-Way ANOVA; (p,0.05).
*vs. CTL11,12,15 or 20d; p,.05.
#vs.G11,12,15 or 20d.
doi:10.1371/journal.pone.0044092.t001
Table 2. The biochemical results for the prevention groups
transplanted with BMSCs.
GROUPS sCr (mg/dl) sU (mg/dl) FENa (%)
CTL10d 0.560.02 2462.0 0.660.02
G10d 1.960.07* 9862.0* 1.560.04*
G10d+BMSC21 1.260.04* 7361.0* 1.260.01*
G10+BMSC5 1.860.03* 8761.0* 2.060.03*
Data are expressed as the mean 6 S.E.M. One-Way ANOVA; (p,0.05).
*vs. CTL10d.
doi:10.1371/journal.pone.0044092.t002
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Flow cytometry
The BMSCs (1–26106) then were characterized by an FACS
analysis that included positive assays (1:250) for anti-CD17-
purified, anti-CD29-FITC, anti-CD44-FITC, anti-CD73- puri-
fied, anti-CD90-FITC, anti-CD106-PE, anti-STRO1-purified and
negative assays for anti-CD11b-purified, anti-CD45-purified and
anti-CD34-FITC (all purchased from BD Pharmagen, California,
USA); one negative control tube with a cell suspension was used as
a control. The cells were incubated with a purified antibody,
washed twice with PBS buffer and incubated with streptavidin-
APC (Becton Dickinson Company, NJ, USA) for 20 minutes. After
the incubation, the cells were washed again with PBS buffer and
resuspended with 500 ml of PBS for the FACS analysis. The flow
cytometry experiments were performed in duplicate.
In Vitro Differentiation Assays
The BMSCs were studied to verify their mesenchymal potential
to differentiate into osteoblasts and adipocytes. The BMSCs were
grown until confluence, and the medium was replaced with the
inductive medium consisting of Iscove’s modified Dulbecco’s
medium, 20% FCS, 100 U/ml penicillin and 100 mg/ml strepto-
mycin supplemented with specific differentiation reagents as
follows:
Osteogenesis. The cells were incubated for 3 weeks, and the
culture media, consisting of 10 mM ß-glycero-phosphate, 50 mg/
ml ascorbic acid 2-phosphate, and 1029 M dexamethasone (all
from Sigma, St. Louis MO, USA), was changed twice a week. The
cells were fixed with 10% formalin, and the mineralization
(presence of calcium-rich hydroxyapatite) of the extracellular
matrix was assessed by staining for 20 min with 2% wt/vol
Alizarin Red S, adjusted to a pH of 4.1 with ammonium
hydroxide (all reagents were from Sigma) [24,25].
Adipogenesis. Cells were incubated for 3 weeks with 5 mg/
ml insulin (Sigma) and 1029 M dexamethasone (Sigma). The
adipogenic differentiation was visualized in phase-contrast micros-
copy by the presence of highly refractive intracellular lipid
vacuoles. Oil Red O (Sigma) staining was used to assay the
accumulation of lipid droplets in these vacuoles [26].
Groups
BMSCs Protocol. Female rats weighing 230–250 g (N= 10
for each group) were divided into groups as shown in Figure 2.
The control group (CTL) was treated with daily i.p. injections of a
vehicle (water), while the G-groups received gentamicin (40 mg/
Kg BW) continuously for 10, 11, 12, 15 or 20 days. For the
prevention groups, the rats received BMSC 16106 i.v. injections
24 hours before (G10d+BMSC21) or on the 5th day (G10d+BMSC5)
of a 10-day treatment with G. For the treated groups, the female
Wistar rats received 16106 BMSC i.v. injections on the 10th day of
G treatment and continued to receive G for an additional 1
(G11+BMSC10), 2 (G12+BMSC10), 5 (G15+BMSC10) or 10 days
(G20+BMSC10) because it is known that the rats may recover
spontaneously from AKI induced by G. The BMSC concentration
was chosen according to previous protocols [27,28]. At the end of
these treatments, the rats were placed in individual metabolic
cages for 24 hours to collect the blood and urine samples used for
the creatinine, urea and sodium measurements.
Conditioned Medium Protocol
As shown in Figure 1, the female rats received G (40 mg/Kg/
BW, i.p., daily) or water (CTL) for 15 or 20 days (N= 10/group).
On the 10th day of the G treatment, the animals received 500 ml of
Figure 3. The light micrographs of the kidney sections were stained with immunofluorescence for Y chromosome (1006) for the
following groups: the Male Wistar rats that received G vehicle (CTL+), the Female Wistar rats that received G vehicle (CTL2), the
Female Wistar rats that received G vehicle and CM on the 10th day (CTL15+CM10), the Female Wistar rats treated with G for 15 days
(G15), the Female Wistar rats treated with G for 15 days and with male BMSCs on the 10th day (G15+BMSC10) and the Female Wistar
rats treated with G for 15 days and MC on the 10th day (G15+MC10). The arrows show the presence of the Y chromosome in the epithelial
tubule cells. The images are magnified 1006.
doi:10.1371/journal.pone.0044092.g003
Table 3. The biochemical results for the treatment groups
transplanted with CM.
GROUPS sCr (mg/dl) sU (mg/dl) FENa (%)
CTL15d 0.760.04 2964.0 0.360.01
G15d 2.760.03* 11961.0* 1.760.03*
G15+CM10 0.660.01# 4161.0*,# 0.760.03#
G15+RNAse10 3.460.08* 12865.1* 2.260.03*
G15+CM+RNAse10 3.160.03* 10664.9* 1.460.03*
G15+TPS10 2.160.09* 10263.3* 1.960.04*
G15+CM+TPS10 1.060.01+ 9962.7*,+ 1.260.02*,+
Data are expressed as the mean ± S.E.M. One-Way ANOVA; (p,0,05).
*vs. CTL; p,.05.
#vs.G15d; p,.05.
+vs.G15+TPS10.
doi:10.1371/journal.pone.0044092.t003
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a single dose of CM delivered intravenously (BMSCs cultured for
12 h with DMEM). In some experiments, the BMSCs were
cultured for 12 h with trypsin at a concentration of 100 ug/ml
(CM+TPS) or RNase A at a concentration of 40 ug/ml, 280 Units
(CM+RNAse) in DMEM without FBS. After this period, the
medium was collected, centrifuged and filtered to remove the cells,
treated with an RNase inhibitor (500 U) and administered to the
rats. Additionally, the rats were treated with DMEM containing
only RNase and trypsin in the same concentrations to account for
the effect of the treatments.
Exosomes were isolated as described [29]. Briefly, the culture
medium collected from the BMSCs was centrifuged for 5 min at
8006g and 10 min at 20006g. The resultant supernatants were
filtered with 0.1 mm pore filters (Millipore), which collected only
100 nm vesicles or smaller, followed by an ultra-centrifugation at
100,0006g for 60 min in a Beckman l-90 ultracentrifuge (Beck-
man Coulter). The resulting pellets were suspended in PBS, pooled
and again ultracentrifuged at 100,0006g for 60 min. The final
pellets of exosomes were suspended in 500 ml of Trizol for RNA
extraction, in RIPA buffer for protein quantification or in PSB for
Figure 4. (A) RT-PCR for 18S RNA in culture medium (CM) from BMSC controls and culture medium treated with RNase (CM+RNAse). (B) BMSC
viability after treatment with Trypsin and RNase by Trypan blue extrusion. (C) The light micrographs of the kidney sections stained with hematoxylin
eosin and with immunochemistry for caspase 3 and KI67. (D) A graphic representation showing the quantitative analysis of the control rat
micrographs (CTL15; CTL15+BMSC10). The histology of the kidney tissue from rats treated with G for 15 days (G15). Some groups presented with
massive tubular necrosis and unstained nuclei (G15, G15+RNAse+CM15), while other groups presented with intensely stained nuclei (G15+BMSC10,
G15+CM10). Data are expressed as the mean 6 S.E.M. (* p,0.05) vs. CTL15d, (# p,0.05) vs. G15.
doi:10.1371/journal.pone.0044092.g004
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animal’s treatment [30]. The exosomes quantification was
analyzed by protein concentration and the animals were treated
with 100 mg/ml of protein.
The protein quantification was analyzed by BCA kit (Bioagency,
USA) according to Lowry methodology. The experiments were
conducted according to the manufacturer’s instructions.
Biochemical and histological analyses
Blood and 24-h urine samples were collected for the analysis of
creatinine (Cr), urea (U) and FENa dosages. Cytokines (IL10,
TNFa and INTc) were analyzed in the group of animals that
received 15 days of treatment with G. The kidneys were examined
by HE, KI67 and caspase 3 staining.
Creatinine was determined by a colorimetric method based on
the Jaffe´ reaction [31] using creatinine assay kits (Labtest, Minas
Gerais, Brazil).
Urea was determined using Urease-Labtest [32], and the renal
tubular function was evaluated by measuring the fractional
excretion of sodium (FENa). The sodium concentrations in the
urine and plasma were determined with a Klina flame photometer
(Becton Dickinson Company, NJ, USA).
ELISA kits (R&D Systems, Minneapolis, Minnesota, USA) were
used to determine the concentrations of cytokines (TNF-a, INF-c,
IL6 and IL10). The plasma levels of cytokines in 10 animals were
determined, as the production of cytokines by epithelial or
inflammatory cells can be detected in the blood stream. The
experiments were conducted according to the manufacturer’s
instructions.
After the experimental protocol, the animals were anesthetized
for renal perfusion through the aorta, and the kidneys were
removed for histological, immunofluorescence and immunochem-
istry studies.
The kidneys were bisected along the non-hilar axis and fixed in
10% phosphate-buffered formalin (Invitrogen, Sa˜o Paulo, Brazil).
These tissues were subsequently embedded in paraffin (Casas
Americanas, Sa˜o Paulo, Brazil), sectioned, and stained with
hematoxylin and eosin (Merck, New Jersey, USA). The kidneys
were examined microscopically by an independent pathologist and
one of the investigators.
Histopathological data were analyzed for tubular necrosis,
proteinaceous casts, and medullar congestion, as suggested by
Solez et al [33], and the changes were quantified.
Immunofluorescence microscopy
To verify the presence of the BMSCs extracted from the male
rats and to characterize their phenotype in the kidney of the
female recipients (Y chromosome), sections of the glomeruli,
Figure 5. (A) Transmission Electron Microscopy of the exossomes-like microvesicles extracted from the BMSC conditioned medium. (B) RT-PCR for
18S RNA of exosome extracted from BMSC culture medium (EXO) untreated and treated with RNase (RNase+EXO). (C) The light micrographs of the
kidney sections stained with hematoxylin eosin. (D) A graphic representation showing the quantitative analysis of the micrographs. The normal
histology of the kidney tissue from control rats (CTL15) and rats treated with G for 15 days (G15). Some groups presented with massive tubular necrosis
and unstained nuclei (G15, G15+RNAse+EXO10), while other groups presented with intensely stained nuclei (G15+EXO10). Data are expressed as the
mean 6 S.E.M. (* p,0.05) vs. CTL15d, (# p,0.05) vs. G15.
doi:10.1371/journal.pone.0044092.g005
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proximal tubular brush border, and renal interstitial area were
stained and analyzed.
The kidneys were fixed in Dubosq-Brazil fluid, routinely
processed, and paraffin wax embedded. The slides were dewaxed
by xylene, taken through graded alcohol washes (at 100, 90, 70,
and 60%) to PBS, and incubated with trypsin (0.1% in CaCl2
0.1%) at 37uC for 15 min.
Frozen sections were treated with 2% bovine serum albumin
and incubated with goat anti-mouse IgG antibody (Invitrogen).
Then, the sections were stained with the primary rat polyclonal
anti-Y-chromosome IgG antibody (1:200) (Santa Cruz Biotech-
nology, New Jersey, USA) overnight at 20uC. A secondary FITC-
conjugated rabbit anti-mouse IgG antibody (1:2000; Invitrogen)
was added before counterstaining with DAPI, and slides were
mounted with Dako Cytomation fluorescent mounting medium
(Dako Cytomation, CA, USA).
Immunofluorescence staining was visualized and recorded with
an Olympus Floview 1000 confocal microscope (OlympusH Bx50,
Olympus, Tokyo, Japan).
In additional experiments, the tubular basement membrane
structures were stained for a more precise localization of Y
chromosome–positive cells.
Proliferation and apoptosis were identified by using immuno-
histochemistry staining. The sections were boiled twice for 5 min
in citrate buffer and were blocked for 30 min in 1% BSA (Sigma,
St. Louis MO, USA) to reduce the background. The tissue sections
were processed for free-floating immunohistochemistry according
to the streptavidin-biotin-peroxidase method.
Briefly, the sections were incubated in 1% H2O2 for 30 min to
quench endogenous peroxidase activity, followed by a permeabi-
lization with a Tris–Triton 0.1% solution, and then were
incubated in 1% BSA for 30 min to block any unspecific binding.
The sections were then incubated overnight at 4uC with primary
antibodies against anti-KI67 (rat monoclonal, 1:200; from Dako)
or cleaved anti-caspase 3 (rat monoclonal, 1:200; Dako) diluted in
Tris HCl 0.1 M (pH 7.4) containing 0.1% bovine serum albumin
(BSA) and 0.3% Triton X-100. In the control experiments, the first
antibody was omitted or replaced by normal serum.
After rinsing, the tissues were incubated for 10 min at room
temperature with a secondary antibody using a DAKO LSABTM
Kit (Dako Cytomation, CA, USA), a labeled streptavidin-biotin
reagent system that includes a biotinylated secondary antibody
plus horseradish-labeled streptavidin-biotin reagents. After rinsing
with Tris buffer, the complex was visualized with a DAKO (Dako
Cytomation, CA, USA) liquid 3,39-diaminobenzidine chromogen
solution.
The tissues were transferred to a buffer solution to stop the
reaction, rinsed again in distilled water and mounted onto
silanized glass slides. The sections were dehydrated through
graded alcohol washes, cleared in xylene and covered with a cover
slip.
All labeled (staining light to dark brown) tubular cells of each
section were counted and averaged for total immunoreactive cells.
Three to four sections per structure or tubular along the kidney
cortex were counted and averaged for each rat. The values
obtained are expressed as the number of positively stained tubulars
6 SEM for 5 animals per group.
Digital photomicrographs were taken through a Nikon Eclipse
E600 upright microscope equipped with Plan Apo objectives and
Figure 6. The plasma cytokine levels in the control (CTL15d and CTL20d), G-treated (G15 and G20) and G-treated rats that received
BMSC (G15 or 20+BMSC10) or CM (G15 or 20+CM10). The data are expressed as the mean6 S.E.M. p,0.05 (*) vs. CTL15 or 20 d; (#) vs. G15 or
20 d; (&) vs. G+BMSC20d.
doi:10.1371/journal.pone.0044092.g006
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connected to a Dell workstation computer through the Pix-
eLINKH Microscope Camera Software (Ottawa, Canada).
RNA isolation, Reverse transcription and Quantitative
Real Time PCR
Total RNA from the BMSC culture medium treated with
RNase (40 mg/ml) was extracted using a Trizol technique
(Invitrogen Life Technologies) according to the manufacturer’s
instructions and published protocol [32]. Reverse transcription
was performed using a High Capacity cDNA Reverse Transcrip-
tion kit for real-time PCR (Applied Biosystems). Primers for 18S
(forward, 59- GAACCAGAGCGAAAGCATTTGCCA -39; re-
verse, 59- TCGGCATCGTTTATGGTCGGAACT -39) were
designed and synthesized by Prodimol. A real-time analysis was
performed on an ABI Prism 7900 (Applied Biosystems) using the
SYBR Green PCR Master Mix for real-time PCR (Applied
Biosystems). The relative expression was determined by a standard
curve.
Transmission Electron Microscopy (TEM)
Exosome pellets were prepared for negative staining. Exosome
pellet (3 ml) was gently placed on 200-mesh Formvar-coated
copper grids, allowed to adsorb for 4–5 min, and processed for
standard uranyl acetate staining. The grid was washed with three
changes of PBS and allowed to semidry at room temperature
before observation in TEM (Jeol 1200 EXII).
Viability
The BMSC viability was analyzed by a Trypan Blue extrusion
followed by a counting of the cells. The results are expressed as
percentages.
Statistical analysis
The results (unless otherwise noted) are expressed as the mean
6 standard error of the mean (SEM). For the renal functional
studies, One-Way variance analysis (ANOVA) was used and was
followed by Dunnett’s test for multiple comparisons. The histology
and immunohistochemistry data were analyzed using the non-
parametric Kruskal-Wallis test or Mann-Whitney test, as appro-
priate. The statistical significance level was defined as P,0.05.
The statistical analyses of the flow cytometry were performed in
the (Cell Quest program, BD Bioscience USA), and these results
are presented as cell percentages. An ANOVA was conducted to
test the comparison among groups using Bartlett’s test for equal
variances and Tukey’s multiple comparison tests.
Supporting Information
Figure S1 Light micrographs of kidney sections stained with
immunofluorescence for Y chromosome (1006). (CTL10) Female
Wistar rats treated with G vehicle during 10 days. (G10) Female
Wistar rats treated with G during 10 days. (G11,12
or20+BMSC10) Female Wistar rats treated with G during 11,
12 or 20 days and BMSC in 10th day. The arrows showed the
presence of Y chromosome in the epithelial tubule cells. Images
magnified 1006.
(TIF)
Figure S2 Numbers of proximal tubules injury for 100 m2 in
female rats treated with G (40 mg/Kg BW) during 10, 12, 15 or
20 days and the 10th day, treated with BMSC (16106, iv).
*p,0.05 vs. G10,12,15 or 20 d.
(TIF)
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